{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:26:00Z","timestamp":1794583560606,"version":"4.9.1"},"reference-count":222,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373058"],"award-info":[{"award-number":["82373058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072484"],"award-info":[{"award-number":["82072484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.seminoncol.2026.152541","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:16Z","timestamp":1787067436000},"page":"152541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework"],"prefix":"10.1016","volume":"53","author":[{"given":"Shang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0001","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0002","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","article-title":"Novel strategies for cancer immunotherapy: counter-immunoediting therapy","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0004","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0005","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0007","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"6832","key":"10.1016\/j.seminoncol.2026.152541_bib0009","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"issue":"6024","key":"10.1016\/j.seminoncol.2026.152541_bib0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"7171","key":"10.1016\/j.seminoncol.2026.152541_bib0011","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12943-024-01973-5","article-title":"The senescence journey in cancer immunoediting","volume":"23","author":"Zingoni","year":"2024","journal-title":"Mol Cancer"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152541_bib0013","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"issue":"5038","key":"10.1016\/j.seminoncol.2026.152541_bib0014","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"issue":"5256","key":"10.1016\/j.seminoncol.2026.152541_bib0016","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0017","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo J"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0018","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1084\/jem.191.5.891","article-title":"Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice","volume":"191","author":"Nishimura","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0019","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0021","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.seminoncol.2026.152541_bib0022","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0023","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2018.10.021","article-title":"The 2018 nobel prize in physiology or medicine: an exemplar of bench to bedside in immunology","volume":"142","author":"Ballas","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0024","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0025","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0028","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0029","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"7559","key":"10.1016\/j.seminoncol.2026.152541_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.seminoncol.2026.152541_bib0031","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0033","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"issue":"6332","key":"10.1016\/j.seminoncol.2026.152541_bib0034","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"6440","key":"10.1016\/j.seminoncol.2026.152541_bib0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aav7062","article-title":"Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses","volume":"364","author":"Sugiura","year":"2019","journal-title":"Science"},{"issue":"36","key":"10.1016\/j.seminoncol.2026.152541_bib222","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0038","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0039","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152541_bib0040","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0126","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0041","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0042","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0043","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0044","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0045","article-title":"Adoptive immune cell therapy for colorectal cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0046","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.seminoncol.2026.152541_bib0047","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.seminoncol.2026.152541_bib0048","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0049","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0051","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.seminoncol.2026.152541_bib0052","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0093","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152541_bib221","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","article-title":"FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy","volume":"31","author":"Barnett","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0053","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0054","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"10.1016\/j.seminoncol.2026.152541_bib0055","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0056","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10427","key":"10.1016\/j.seminoncol.2026.152541_bib0057","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"7963","key":"10.1016\/j.seminoncol.2026.152541_bib0058","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0059","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","author":"Wong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0060","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.seminoncol.2026.152541_bib0036","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0061","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0062","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0063","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0064","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"10466","key":"10.1016\/j.seminoncol.2026.152541_bib0065","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0066","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152541_bib0067","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152541_bib0037","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0068","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152541_bib0069","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70022","article-title":"Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: final analysis from a phase 1b study","volume":"131","author":"Milhem","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0070","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152541_bib0071","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0072","article-title":"Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis","volume":"13","author":"Zou","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0073","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0074","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"issue":"6529","key":"10.1016\/j.seminoncol.2026.152541_bib0075","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.seminoncol.2026.152541_bib0076","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0077","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41467-024-46450-1","article-title":"Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors","volume":"15","author":"Gil-Jimenez","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0078","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12885-025-13484-7","article-title":"The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1602452","article-title":"Role of TGF\u03b2-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy","volume":"15","author":"Hou","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0080","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41467-024-46504-4","article-title":"Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas","volume":"15","author":"Broz","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0081","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0082","article-title":"Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives","volume":"14","author":"Jiang","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0083","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091127","article-title":"Targeting the adenosine A2A receptor as a novel therapeutic approach for renal cell carcinoma: mechanisms and clinical trial review","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152541_bib0084","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14681","article-title":"ADPORT-601: first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors","volume":"42","author":"Fong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10585-023-10217-7","article-title":"Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis","volume":"40","author":"Tian","year":"2023","journal-title":"Clin Exp Metastasis"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0086","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"10400","key":"10.1016\/j.seminoncol.2026.152541_bib0087","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.seminoncol.2026.152541_bib0088","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0089","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152541_bib0091","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152541_bib0092","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0094","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.24.00953","article-title":"Comparative analysis of intracranial response assessment criteria in patients with melanoma brain metastases treated with combination nivolumab + ipilimumab in CheckMate 204","volume":"43","author":"Huang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0095","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0096","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41419-024-06726-2","article-title":"Role of T cells in liver metastasis","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152541_bib0097","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0098","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0099","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0100","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0101","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152541_bib0102","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152541_bib0103","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0104","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"issue":"10459","key":"10.1016\/j.seminoncol.2026.152541_bib0105","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0106","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152541_bib0107","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0108","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jtho.2024.03.002","article-title":"Precision immunotherapy for STK11\/KEAP1-mutant NSCLC","volume":"19","author":"Ricciuti","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0109","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0110","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-023-02482-w","article-title":"Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases","volume":"130","author":"Qu","year":"2024","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0112","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0113","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.seminoncol.2026.152541_bib0114","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0115","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0116","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009495","article-title":"Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214","volume":"12","author":"Mantia","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0117","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0118","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"10397","key":"10.1016\/j.seminoncol.2026.152541_bib0119","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0120","first-page":"58","article-title":"Kidney cancer updates from the 2023 American society of clinical oncology annual meeting in Chicago","volume":"21","author":"Elias","year":"2023","journal-title":"Kidney Cancer J"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0121","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152541_bib0122","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0123","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0124","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0127","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102179","article-title":"Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"63","author":"Kulkarni","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0129","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0131","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0132","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci (Basel)"},{"issue":"19","key":"10.1016\/j.seminoncol.2026.152541_bib0133","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.seminoncol.2026.152541_bib0134","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0136","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0137","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115395","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study","volume":"221","author":"Tahara","year":"2025","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.seminoncol.2026.152541_bib0139","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.23.02625","article-title":"Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial","volume":"42","author":"Dzienis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0140","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41467-024-45714-0","article-title":"Gene-expression-based T-cell-to-stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer","volume":"15","author":"Rijnders","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0141","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41698-024-00665-z","article-title":"Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities","volume":"8","author":"Lozac'hmeur","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"7517","key":"10.1016\/j.seminoncol.2026.152541_bib0142","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0143","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0144","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"issue":"10418","key":"10.1016\/j.seminoncol.2026.152541_bib0145","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0146","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0147","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.seminoncol.2026.152541_bib0148","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152541_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103962","article-title":"Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups","volume":"9","author":"Leone","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152541_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4132\/jptm.2024.03.15","article-title":"Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists","volume":"58","author":"Ahn","year":"2024","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0151","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12029-023-01003-5","article-title":"Management of microsatellite instability high (MSI-H) gastroesophageal adenocarcinoma","volume":"55","author":"Zhou","year":"2024","journal-title":"J Gastrointest Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0152","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152541_bib0153","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152541_bib0154","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152541_bib0155","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0156","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41523-024-00679-7","article-title":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC","volume":"10","author":"Im","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152541_bib0157","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0158","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-023-01724-2","article-title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","volume":"25","author":"Sigurjonsdottir","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217865","article-title":"The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): emerging therapeutic opportunities","volume":"628","author":"Sabit","year":"2025","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0161","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122995","article-title":"Interactions between Cancer-associated fibroblasts and T cells in the pancreatic tumor microenvironment and the role of chemokines","volume":"13","author":"Gorchs","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"50","key":"10.1016\/j.seminoncol.2026.152541_bib0162","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152541_bib0163","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"issue":"8056","key":"10.1016\/j.seminoncol.2026.152541_bib0164","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0165","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","article-title":"Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study","volume":"25","author":"Van Laethem","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0166","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2543614","article-title":"A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophages","volume":"14","author":"Bever","year":"2025","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0167","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41590-025-02134-6","article-title":"Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer","volume":"26","author":"Shakiba","year":"2025","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0168","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0169","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152541_bib0170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0171","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152541_bib0172","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015037","article-title":"Glioblastoma immunotherapy: a systematic review of the present strategies and prospects for advancements","volume":"24","author":"Agosti","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0173","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","article-title":"Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy","volume":"9","author":"Zhao","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0174","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0175","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0176","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0177","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","article-title":"Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas","volume":"15","author":"Arrieta","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0178","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0179","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11060-023-04549-3","article-title":"Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis","volume":"166","author":"Arora","year":"2024","journal-title":"J Neurooncol"},{"issue":"1184","key":"10.1016\/j.seminoncol.2026.152541_bib0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/postmj\/qgad136","article-title":"Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies","volume":"100","author":"Han","year":"2024","journal-title":"Postgr Med J"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0181","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s11912-024-01583-w","article-title":"Immunotherapy for microsatellite-stable metastatic colorectal cancer: can we close the gap between potential and practice?","volume":"26","author":"Hamid","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0182","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0183","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0184","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0185","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0186","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0187","first-page":"1771","article-title":"Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. a literature review","volume":"18","author":"Aruquipa","year":"2024","journal-title":"Ecancermedicalscience"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152541_bib0188","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.2023022921","article-title":"Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia","volume":"145","author":"Badar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105872","article-title":"Tandem CD19\/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r\/r B-ALL","volume":"118","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0190","article-title":"Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0191","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","article-title":"Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease","volume":"109","author":"Kayser","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0192","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s44313-025-00077-3","article-title":"Atypical features of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after inotuzumab ozogamicin in adult patients with acute lymphoblastic leukemia","volume":"60","author":"Sung","year":"2025","journal-title":"Blood Res"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152541_bib0193","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225827","article-title":"Immunotherapy for diffuse large B-cell lymphoma: current landscape and future directions","volume":"13","author":"Modi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152541_bib0194","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152541_bib0195","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152541_bib0196","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0197","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00925","article-title":"Five-year outcomes of the POLARIX study comparing pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma","author":"Morschhauser","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152541_bib0198","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152541_bib0199","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0200","first-page":"418","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152541_bib0201","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152541_bib0202","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.seminoncol.2026.152541_bib0203","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152541_bib0204","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152541_bib0205","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0206","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2018.00193","article-title":"Cancer immunotherapy and the immune response in hodgkin lymphoma","volume":"8","author":"Renner","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0207","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9513701","article-title":"Immune checkpoint inhibition in classical hodgkin lymphoma: from early achievements towards new perspectives","volume":"2019","author":"De Goycoechea","year":"2019","journal-title":"J Oncol"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152541_bib0208","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152541_bib0209","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0210","doi-asserted-by":"crossref","unstructured":"Ansell S.M., Connors J.M., Radford J.A., Kim W.S., Gallamini A., Ramchandren R., et al., First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical hodgkin lymphoma: an updated analysis of ECHELON-1, J Clin Oncol. 40(16_suppl) 7503. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7503.","DOI":"10.1200\/JCO.2022.40.16_suppl.7503"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0211","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152541_bib0212","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152541_bib0213","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6349","key":"10.1016\/j.seminoncol.2026.152541_bib0214","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.seminoncol.2026.152541_bib0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","article-title":"Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment","volume":"1036","author":"Gajewski","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152541_bib0216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152541_bib0217","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152541_bib0218","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.seminoncol.2026.152541_bib0219","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:28:55Z","timestamp":1794580135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":222,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0093775426000862"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152541","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152541"}}